Single peptide Vial strength 20 mg
Cartalax20 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Cartalax, explained simply
A short bioregulatory peptide examined in research on connective tissue and fibroblast activity.
Research area
Connective tissue and cellular ageing
How it works
Preclinical literature explores possible influences on gene expression and fibroblast function.
Why it matters
Interest centres on connective tissue maintenance and age-related cellular processes.
What has been observed
Reported observations come chiefly from experimental models and are not confirmed clinical outcomes.
Effects and points to consider
Despite its cartilage-related name, this profile should not be read as a promise of joint repair in people.
01 / Vial strength 20 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 20 mg Cartalax |
|---|---|
| Final volume | 3 mL |
| Concentration | 6.67 mg/mL |
| One U-100 unit | 66.67 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week/Phase | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 2,000 mcg (2.0 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 3,000 mcg (3.0 mg) | 45 units (0.45 mL) |
| Weeks 5–8 | 4,000 mcg (4.0 mg) | 60 units (0.60 mL) |
| Weeks 9–12 | 5,000 mcg (5.0 mg) | 75 units (0.75 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.